For example, the overexpression of epidermal growth factor receptor (EGFR), which is involved in about 60% of NSCLC tumors and present in about 20% of LUAD tumors, currently has precision medicine implications in treating lung cancer [13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.